ABSTRACT
Assessment of the safety of investigational agents is a major objective of most clinical trials. Safety is assessed by the reporting of subject adverse events (adverse experiences or side effects) as well as the assessment of changes in clinical laboratory results, electrocardiogram (ECG) patterns, subject physical examinations, and vital signs. Serious and unexpected adverse events are subject to prompt Food and Drug Administration (FDA) reporting requirements.
